Candel Therapeutics (Series C)
Funding Details
- Awarder
- Inbox
- Date Award
- April 02, 2019
- Vertical
- Immuno-oncology
- Funding URL
- View Funding Page
- Funding Amount:
- $22,500,000
Company Info
- Founders
- Estuardo Aguilar-Cordova
- Company Description
- Advantagene, Inc. d.b.a. Candel Therapeutics is developing proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors.
- Market
- Solid tumors
- Location
- Auburndale, MA, USA
- Coinvestors
- H7 Holdings, Level One Partners, Northpond Ventures, Sands Capital